Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence

• Published in: The oncologist (Dayton, Ohio) Vol. 25; no. 1; pp. e147 - e159
• Main Authors: Klempner, Samuel J., Fabrizio, David, Bane, Shalmali, Reinhart, Marcia, Peoples, Tim, Ali, Siraj M., Sokol, Ethan S., Frampton, Garrett, Schrock, Alexa B., Anhorn, Rachel, Reddy, Prasanth
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.01.2020
• Subjects: Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal - therapeutic use; Antibodies/therapeutic use; Biomarkers, Tumor; DNA; DNA mutational analysis; Genes; Humans; Immunotherapy - methods; Immuno‐Oncology; Mutation; Neoplasm; Programmed cell death 1 receptor; Sequence analysis; Treatment Outcome; Tumor Burden; Neoplasm; DNA mutational analysis; DNA; Genes; Programmed cell death 1 receptor; Sequence analysis; Antibodies/therapeutic use

Treatment with immune checkpoint inhibitors (ICPIs) extends survival in a proportion of patients across multiple cancers. Tumor mutational burden (TMB)—the number of somatic mutations per DNA megabase (Mb)—has emerged as a proxy for neoantigen burden that is an independent biomarker associated with...